Adagene, Inc. (ADAG)
2.58
+0.09
(+3.61%)
USD |
NASDAQ |
Oct 27, 16:00
2.58
0.00 (0.00%)
After-Hours: 20:00
Adagene Enterprise Value : 260.51M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 260.51M |
| October 26, 2026 | 254.47M |
| October 23, 2026 | 249.09M |
| October 22, 2026 | 251.11M |
| October 21, 2026 | 249.09M |
| October 20, 2026 | 255.14M |
| October 19, 2026 | 241.04M |
| October 16, 2026 | 225.59M |
| October 15, 2026 | 248.42M |
| October 14, 2026 | 241.04M |
| October 13, 2026 | 252.45M |
| October 12, 2026 | 271.25M |
| October 09, 2026 | 272.59M |
| October 08, 2026 | 273.94M |
| October 07, 2026 | 275.95M |
| October 06, 2026 | 284.01M |
| October 05, 2026 | 275.28M |
| October 02, 2026 | 278.64M |
| October 01, 2026 | 284.01M |
| September 30, 2026 | 302.14M |
| September 29, 2026 | 302.81M |
| September 28, 2026 | 302.14M |
| September 25, 2026 | 284.01M |
| September 24, 2026 | 287.37M |
| September 23, 2026 | 286.70M |
| Date | Value |
|---|---|
| September 22, 2026 | 304.15M |
| September 21, 2026 | 302.81M |
| September 18, 2026 | 309.52M |
| September 17, 2026 | 313.55M |
| September 16, 2026 | 300.12M |
| September 15, 2026 | 286.70M |
| September 14, 2026 | 306.84M |
| September 11, 2026 | 315.57M |
| September 10, 2026 | 309.52M |
| September 09, 2026 | 306.84M |
| September 08, 2026 | 321.61M |
| September 04, 2026 | 327.65M |
| September 03, 2026 | 335.04M |
| September 02, 2026 | 335.04M |
| September 01, 2026 | 331.68M |
| August 31, 2026 | 322.95M |
| August 28, 2026 | 334.37M |
| August 27, 2026 | 349.14M |
| August 26, 2026 | 345.78M |
| August 25, 2026 | 343.77M |
| August 24, 2026 | 349.14M |
| August 21, 2026 | 357.20M |
| August 20, 2026 | 361.90M |
| August 19, 2026 | 363.91M |
| August 18, 2026 | 359.21M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascletis Pharma, Inc. | 667.59M |
| CStone Pharmaceuticals Co. Ltd. | 974.27M |
| RemeGen Co., Ltd. | 4.874B |
| InnoCare Pharma Ltd. | 1.921B |
| JW (Cayman) Therapeutics Co. Ltd. | -- |
Enterprise Value Related Metrics
| Earnings Yield | -14.63% |
| Normalized Earnings Yield | -14.19 |